EUVIMEDEUVIMED entdecken
Beobachtungsstudie

Impact of elexacaftor/tezacaftor/ivacaftor on biomarkers of cystic fibrosis hepatobiliary involvement in the PUSH study

Wen Ye, John C Magee, Suiyuan Huang, Daniel H Leung, Molly Bozic, Janis Stoll, Simon C Ling, Shruti M Paranjape, Wikrom Karnsakul, A Jay Freeman, Sarah Jane Schwarzenberg, Joseph Palermo und 12 weitere

Journal of Pediatric Gastroenterology and Nutrition · 2026

DOI: 10.1002/jpn3.70290 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Journal of Pediatric Gastroenterology and Nutrition, 2026. Verfasst von Wen Ye und 23 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biostatistics, University of Michigan Medical School, Ann Arbor, Michigan, USA. Hauptthemen laut MEDLINE: Cystic Fibrosis, Aminophenols, Benzodioxoles, Quinolones. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 11 Literaturangaben. Gefördert von: Cystic Fibrosis Foundation, NIDDK NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

The impact of elexacaftor/tezacaftor/ivacaftor (ETI) on cystic fibrosis (CF) hepatobiliary involvement (CFHBI) is uncertain. The goal of this study was to investigate the changes in key liver parameters in PUSH study participants who started ETI compared to those who did not (noETI).

Methods

PUSH was a prospective observational study of persons with CF (pwCF) (3–12 yo at PUSH entry). Linear mixed effect model (LMEM) with one knot tested if ETI changed the slope of trajectories of clinical parameters by comparing ETI to noETI. Index time (IT) for ETI was ETI start and time of ETI availability for noETI. Time zero in the LMEM was index time.

Results

One hundred forty‐seven participants (104 ETI, 43 noETI). At IT, the groups were similar, for age, and liver parameters. Mean duration of ETI use was 22 months. The annual rate of change over time after IT in ETI compared to noETI was significantly improved for FEV 1 % pre (+3.4/yr p = 0.02) and wt z score (+0.06/yr, p = 0.006). There was improvement for ETI vs noETI for GGT (−15%/yr, p = 0.01) and ALT (−12%/yr, p = 0.02). Participants with CFHBI on ETI demonstrated similar trends and also had improvements in GGT and GGT to platelet ratio (GPR), but there were no differences in liver stiffness or US classification changes.

Conclusions

GGT and GPR improve in pwCF and CFHBI who received ETI compared to noETI. There were no changes in other liver parameters. This suggests an early signal for positive impact on CFHBI, but no early improvement in fibrosis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cystic FibrosisAminophenolsBenzodioxolesQuinolonesIndolesPyrrolidinesPyridinesPyrazolesLiver DiseasesHumansMaleFemaleProspective StudiesBiomarkersDrug CombinationsChildAdolescentChloride Channel AgonistsLiverQuinolines

Stichwörter der Autor:innen

GGT to platelet ratiocystic fibrosis liver involvementfibrosis indiceshighly effective modulator treatmentliver ultrasound

Substanzen

AminophenolsBenzodioxolesQuinolonesBiomarkersDrug CombinationsIndolesPyrrolidinesPyridinesivacaftorChloride Channel Agonists

Autor:innen und Institutionen

  • Department of Biostatistics, University of Michigan Medical School, Ann Arbor, Michigan, USA.
  • Department of Surgery, University of Michigan Medical School, Ann Arbor, Michigan, USA.
  • Department of Pediatrics, Baylor College of Medicine, Division of Gastroenterology, Hepatology and Nutrition, Texas Children's Hospital, Houston, Texas, USA.
  • Pediatric Gastroenterology, Hepatology and Nutrition, Riley Hospital for Children/Indiana University School of Medicine, Indianapolis, Indiana, USA.
  • Division of Pediatric Gastroenterology, Hepatology and Nutrition, Washington University School of Medicine, St Louis, Missouri, USA.
  • Division of Gastroenterology, Hepatology and Nutrition, The Hospital for Sick Children, Department of Paediatrics, University of Toronto, Toronto, Ontario, Canada.

ORCID-Profile: Michael R Narkewicz

Förderung

  • Cystic Fibrosis Foundation
  • NIDDK NIH HHS

Zitieren

APA

Ye, W., Magee, J. C., Huang, S., Leung, D. H., Bozic, M., Stoll, J., C Ling, S., Paranjape, S. M., Karnsakul, W., Jay Freeman, A., Schwarzenberg, S. J., Palermo, J., Alonso, E., Green, N., Masand, P., Karmazyn, B., Harned, R., Navarro, O. M., Siegel, M. J., …, & Narkewicz, M. R. (2026). Impact of elexacaftor/tezacaftor/ivacaftor on biomarkers of cystic fibrosis hepatobiliary involvement in the PUSH study. Journal of Pediatric Gastroenterology and Nutrition. https://doi.org/10.1002/jpn3.70290

Vancouver

Ye W, Magee JC, Huang S, Leung DH, Bozic M, Stoll J, et al. Impact of elexacaftor/tezacaftor/ivacaftor on biomarkers of cystic fibrosis hepatobiliary involvement in the PUSH study. Journal of Pediatric Gastroenterology and Nutrition. 2026. doi:10.1002/jpn3.70290

BibTeX
@article{Ye2026,
  author = {Ye, Wen and Magee, John C and Huang, Suiyuan and Leung, Daniel H and Bozic, Molly and Stoll, Janis and C Ling, Simon and Paranjape, Shruti M and Karnsakul, Wikrom and Jay Freeman, A and Schwarzenberg, Sarah Jane and Palermo, Joseph and Alonso, Estella and Green, Nicole and Masand, Prakash and Karmazyn, Boaz and Harned, Roger and Navarro, Oscar M and Siegel, Marilyn J and Towbin, Alex and Alazraki, Adina and Otto, Randolph K and Nicholas, Jennifer L and Narkewicz, Michael R},
  title = {Impact of elexacaftor/tezacaftor/ivacaftor on biomarkers of cystic fibrosis hepatobiliary involvement in the PUSH study},
  journal = {Journal of Pediatric Gastroenterology and Nutrition},
  year = {2026},
  doi = {10.1002/jpn3.70290}
}
Kostenlos starten →